Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 3/2014

01.04.2014 | Original Paper

Prevalence of HIV Infection and Risk Behaviors Among Younger and Older Injecting Drug Users in the United States, 2009

verfasst von: Dita Broz, Huong Pham, Michael Spiller, Cyprian Wejnert, Binh Le, Alan Neaigus, Gabriela Paz-Bailey

Erschienen in: AIDS and Behavior | Sonderheft 3/2014

Einloggen, um Zugang zu erhalten

Abstract

This study compared HIV sero-prevalence and risk behaviors between younger and older injecting drug users (IDUs). IDUs aged ≥18 years were interviewed for the 2009 National HIV Behavioral Surveillance System. Using GEE regression, we assessed characteristics of younger (18–29 years) and older (≥30 years) IDUs, and factors associated with past 12-month receptive syringe sharing and unprotected sex (vaginal/anal). Of 10,090 participants, 10 % were younger. HIV sero-prevalence was lower among younger than older IDUs (4 vs. 10 %, p = 0.001). Younger IDUs were more likely (p ≤ 0.002) to be non-black race/ethnicity, report higher household income, homelessness, being arrested and to engage in receptive syringe sharing and unprotected sex. In multivariable models, age remained associated (p < 0.001) with receptive syringe sharing (aPR = 1.14, 95 % CI1.07–1.22) and unprotected sex (aPR = 1.10, 95 % CI1.06–1.14). Although younger IDUs had lower HIV prevalence, their behaviors place them at increased risk of HIV infection and could lead to a rapid spread in this susceptible population.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
CDC. Estimated HIV Incidence in the United States, 2007–2010. HIV surveill suppl rep 2012; 17 (4).
2.
CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. dependent areas—2010. HIV HIV surveill suppl rep 2012; 17 (3, part A).
3.
4.
Cooper H, Friedman SR, Tempalski B, Friedman R, Keem M. Racial/ethnic disparities in injection drug use in large US metropolitan areas. Ann Epidemiol. 2005;15(5):326–34.PubMedCrossRef
5.
Estrada AL. Health disparities among African-American and hispanic drug injectors—HIV, AIDS, hepatitis B virus and hepatitis C virus: a review. AIDS. 2005;19(Suppl 3):S47–52.PubMedCrossRef
6.
Des Jarlais DC, McCarty D, Vega WA, Bramson H. HIV infection among people who inject drugs: the challenge of racial/ethnic disparities. Am Psychol. 2013;68(4):274–85.PubMedCrossRef
7.
CDC. HIV infection and HIV-associated behaviors among injecting drug users—20 cities, United States, 2009. MMWR. 2012;61(8):133–8.
8.
Fennema JS, Van Ameijden EJ, Van Den Hoek A, Coutinho RA. Young and recent-onset injecting drug users are at higher risk for HIV. Addict. 1997;92(11):1457–65.CrossRef
9.
Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T- lymphotropic viruses. Am J Public Health. 1996;86(5):655–61.PubMedCentralPubMedCrossRef
10.
van Ameijden EJ, van den Hoek JA, Hartgers C, Coutinho RA. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. Am J Epidemiol. 1994;139(12):1153–63.PubMed
11.
Nelson KE, Galai N, Safaeian M, Strathdee SA, Celentano DD, Vlahov D. Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988–1998. Am J Epidemiol. 2002;156(7):641–53.PubMedCrossRef
12.
Kral AH, Lorvick J, Edlin BR. Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr. 2000;24(2):162–7.PubMedCrossRef
13.
Hagan H, Des Jarlais DC, Stern R, et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy. 2007;18(5):341–51.PubMedCrossRef
14.
Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013;57(Suppl 2):S32–8.PubMedCrossRef
15.
Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS. 2000;14(6):717–26.PubMedCrossRef
16.
Rondinelli AJ, Ouellet LJ, Strathdee SA, et al. Young adult injection drug users in the United States continue to practice HIV risk behaviors. Drug Alcohol Depend. 2009;104(1–2):167–74.PubMedCrossRef
17.
Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis. 2000;30(3):579–81.PubMedCrossRef
18.
Broz D, Ouellet LJ. Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug Alcohol Depend. 2008;94(1–3):221–33.PubMedCentralPubMedCrossRef
19.
Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson K, Vlahov D. Prevalence and incidence of hepatitis C infection among young adult injection drug users. J Acquir Immune Defic Syndr. 1998;18(Suppl 1):S11–9.CrossRef
20.
Coyle SL, Needle RH, Normand J. Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Rep. 1998;113(Suppl 1):19–30.PubMedCentralPubMed
21.
22.
Des Jarlais DC, Semaan S. HIV prevention research: cumulative knowledge or accumulating studies? an introduction to the HIV/AIDS prevention research synthesis project supplement. J Acquir Immune Defic Syndr. 2002;30(Suppl 1):S1–7.PubMedCrossRef
23.
Stimson G, Alldritt L, Dolan K, Donoghoe M. Preventing the spread of HIV in injecting drug users–the experience of syringe-exchange schemes in England and Scotland. NIDA Res Monogr. 1988;90:302–10.PubMed
24.
Chitwood DD, Mccoy CB, Comerford M, Kitner K. The prevalence and incidence of HIV among injection drug users: a five year panel study. popul res Policy Rev. 1999;18:39–53.CrossRef
25.
Des Jarlais DC, Perlis T, Arasteh K, et al. HIV Incidence among injection drug users in New York City, 1990 to 2002: use of Serologic Test Algorithm to assess expansion of HIV prevention services. Am J Public Health. 2005;95(8):1439–44.PubMedCentralPubMedCrossRef
26.
Ouellet LJ, Thorpe LE, Huo D, et al. Prevalence and incidence of HIV among out-of-treatment injecting drug users, Chicago 1994-1996. J Acquir Immune Defic Syndr. 2000;25(5):443–50.PubMedCrossRef
27.
Hahn JA, Evans JL, Davidson PJ, Lum PJ, Page K. Hepatitis C virus risk behaviors within the partnerships of young injecting drug users. Addiction. 2010;105(7):1254–64.PubMedCentralPubMedCrossRef
28.
Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009;200(8):1216–26.PubMedCentralPubMedCrossRef
29.
CDC. Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users—new York, November 2004-April 2007. MMWR. 2008;57(19):517–21.
30.
CDC. Notes from the field : hepatitis C virus infections among young adults—rural Wisconsin, 2010. MMWR. 2012;61(19):358.
31.
CDC. Hepatitis C virus infection among adolescents and young adults-Massachusetts, 2002-2009. MMWR. 2011; 60(17).
32.
Tempalski B, Pouget ER, Cleland CM, et al. Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007. PLoS ONE. 2013;8(6):e64789.PubMedCentralPubMedCrossRef
33.
Gallagher KM, Sullivan PS, Lansky A, Onorato IM. Behavioral surveillance among people at risk for HIV infection in the U.S.: the National HIV Behavioral Surveillance System. Public Health Rep. 2007;122(Suppl 1):32–8.PubMedCentralPubMed
34.
Lansky A, Abdul-Quader AS, Cribbin M, et al. Developing an HIV behavioral surveillance system for injecting drug users: the National HIV Behavioral Surveillance System. Public Health Rep. 2007;122(Suppl 1):48–55.PubMedCentralPubMed
35.
36.
Allen DR, Finlayson T, Abdul-Quader A, Lansky A. The role of formative research in the National HIV Behavioral Surveillance System. Public Health Rep. 2009;124(1):26–33.PubMedCentralPubMed
37.
Heckathorn D. Respondent-driven sampling: a new approach to the study of hidden population. Soc Probl. 1997;44(2):174–99.CrossRef
38.
Le Marchand C, Evans J, Page K, Davidson PJ, Hahn JA. Hazardous alcohol consumption among young adult IDU and its association with high risk behaviors. Drug Alcohol Depend. 2013;127(1–3):143–9.PubMedCentralPubMedCrossRef
39.
40.
41.
Heckathorn DD. Extensions of Respondent-Driven Sampling: analyzing continuous variables and controlling for differential recruitment. Sociol Method. 2007;34:193–239.
42.
Gile KJ. Improved inference for respondent-driven sampling data with application to HIV prevalence estimation. J Am Stat Assoc. 2011;106(493):135–46.CrossRef
43.
Gile KJ, Handcock MS. Network model-assisted inference from respondent-driven sampling data. arXiv:1108.0298. 2011.
44.
Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121–30.PubMedCrossRef
45.
Wagner KD, Pollini RA, Patterson TL, et al. Cross-border drug injection relationships among injection drug users in Tijuana, Mexico. Drug Alcohol Depend. 2011;113(2–3):236–41.PubMedCentralPubMedCrossRef
46.
Frost SD, Brouwer KC, Firestone Cruz MA, et al. Respondent-driven sampling of injection drug users in two U.S.-Mexico border cities: recruitment dynamics and impact on estimates of HIV and syphilis prevalence. J Urban Health. 2006;83(6 Suppl):i83–97.PubMedCrossRef
47.
Szwarcwald CL, De Souza Junior PR, Damacena GN, Junior AB, Kendall C. Analysis of data collected by RDS among sex workers in 10 Brazilian cities, 2009: estimation of the prevalence of HIV, variance, and design effect. J Acquir Immune Defic Syndr. 2011;57(Suppl 3):S129–35.PubMedCrossRef
48.
Skov T, Deddens J, Petersen MR, Endahl L. Prevalence proportion ratios: estimation and hypothesis testing. Int J Epidemiol. 1998;27(1):91–5.PubMedCrossRef
49.
Strathdee SA, Galai N, Safaiean M, et al. Sex differences in risk factors for HIV seroconversion among injection drug users: a 10-year perspective. Arch Intern Med. 2001;161(10):1281–8.PubMedCrossRef
50.
Becker Buxton M, Vlahov D, Strathdee SA, et al. Association between injection practices and duration of injection among recently initiated injection drug users. Drug and alcohol dependence. 2004;75(2):177–83.PubMedCrossRef
51.
Cassin S, Geoghegan T, Cox G. Young injectors: a comparative analysis of risk behaviour. Ir J Med Sci. 1998;167(4):234–7.PubMedCrossRef
52.
Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology. 2002;36(3):737–42.PubMedCrossRef
53.
Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357(9266):1397–401.PubMedCrossRef
54.
Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman DC, Semaan S. Associations between herpes simplex virus type 2 and HCV With HIV among injecting drug users in New York City: the current importance of sexual transmission of HIV. Am J Public Health. 2011;101(7):1277–83.PubMedCentralPubMedCrossRef
55.
56.
Novelli LA, Sherman SG, Havens JR, Strathdee SA, Sapun M. Circumstances surrounding the first injection experience and their association with future syringe sharing behaviors in young urban injection drug users. Drug Alcohol Depend. 2005;77(3):303–9.PubMedCrossRef
57.
Nelson KE, Vlahov D, Solomon L, Cohn S, Muñoz A. Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, MD. Arch Intern Med. 1995;155:1305–11.PubMedCrossRef
58.
Des Jarlais DC, Perlis T, Friedman SR, et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. Am J Public Health. 1998;88(12):1801–6.PubMedCentralPubMedCrossRef
59.
Carneiro M, Fuller C, Doherty MC, Vlahov D. HIV prevalence and risk behaviors among new initiates into injection drug use over the age of 40 years old. Drug Alcohol Depend. 1999;54(1):83–6.PubMedCrossRef
60.
Kleinman PH, Goldsmith DS, Friedman SR, Hopkins W. Des Jarlais DC. Knowledge about and behaviors affecting the spread of AIDS: a street survey of intravenous drug users and their associates in New York City. Int J Addict. 1990;25(4):345–61.PubMed
61.
O’Sullivan LF, Udell W, Patel VL. Young urban adults’ heterosexual risk encounters and perceived risk and safety: a structured diary study. J Sex Res. 2006;43(4):343–51.PubMedCrossRef
62.
Bailey SL, Ouellet LJ, Mackesy-Amiti ME, et al. Perceived risk, peer influences, and injection partner type predict receptive syringe sharing among young adult injection drug users in five U.S. cities. Drug Alcohol Depend. 2007;91(Suppl 1):S18–29.PubMedCrossRef
63.
Galea S, Vlahov D. Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Rep. 2002;117(Suppl 1):S135–45.PubMedCentralPubMed
64.
Coady MH, Latka MH, Thiede H, et al. Housing status and associated differences in HIV risk behaviors among young injection drug users (IDUs). AIDS Beh. 2007;11(6):854–63.CrossRef
65.
Wood E, Li K, Small W, Montaner JS, Schechter MT, Kerr T. Recent incarceration independently associated with syringe sharing by injection drug users. Public Health Rep. 2005;120(2):150–6.PubMedCentralPubMed
66.
Koblin BA, Chesney MA, Husnik MJ, et al. High-risk behaviors among men who have sex with men in 6 US cities: baseline data from the EXPLORE study. Am J Public Health. 2003;93(6):926–32.PubMedCentralPubMedCrossRef
67.
Williams LA, Klausner JD, Whittington WL, Handsfield HH, Celum C, Holmes KK. Elimination and reintroduction of primary and secondary syphilis. Am J Public Health. 1999;89(7):1093–7.PubMedCentralPubMedCrossRef
68.
CDC. Increases in unsafe sex and rectal gonorrhea among men who have sex with men, San Francisco, 1994-1997. MMWR. 1999; 48(3).
69.
70.
Johnson BD, Golub A. Generational trends in heroin use and injection in New York City. In: Musto DF, editor. One hundred years of heroin. Westport: Auburn House of Greenwood; 2002. p. 92–128.
71.
Johnson BD, Williams T, Kojo AD, Sanabria H. Drug abuse in the inner city: impact on hard-drug users and the community. In: Tonry M, Wilson JQ, editors. Drug and crime (crime and justice: a review of research, 13). Chicago: University of chicago press; 1990. p. 9–67.
72.
Hunt LB, Chambers CD. The Heroin Epidemics. A study of Heroin Use in the United States, 1965-1975. New York: NY: Spectrum; 1976.
73.
CDC. HIV infection among injection-drug users—34 States, 2004–2007. MMWR. 2009;58(46):1291–5.
74.
Johnson BD, Thomas G, Golub A. Trends in heroin use among Manhattan arrestees from the heroin and crack eras. In: Inciardi JA, Harrison LD, editors. Heroin in the Age of Crack Cocaine. Thousand Oaks: Sage; 1998. p. 109–30.
75.
Boyle JM, Brunswick AF. What happened in Harlem? analysis of a decline in heroin use among a generation unit of urban black youth. J Drug Issues. 1980;10(1):109–30.
76.
Des Jarlais DC, Friedman SR, Perlis T, et al. Risk behavior and HIV infection among new drug injectors in the era of AIDS in New York City. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20(1):67–72.PubMedCrossRef
77.
Fuller CM, Vlahov D, Ompad DC, Shah N, Arria A, Strathdee SA. High-risk behaviors associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: a case-control study. Drug Alcohol Depend. 2002;66(2):189–98.PubMedCrossRef
78.
Garfein RS, Golub ET, Greenberg AE, et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS. 2007;21(14):1923–32.PubMedCrossRef
79.
Neaigus A, Friedman SR, Jose B, et al. High-risk personal networks and syringe sharing as risk factors for HIV infection among new drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:499–509.PubMedCrossRef
80.
Des Jarlais DC, Perlis T, Arasteh K, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS. 2005;19(Supplement 3):S20–5.PubMedCrossRef
81.
Pouget ER, Deren S, Fuller CM, et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. JAIDS. 2005;39(4):471–7.PubMed
82.
Huo D, Ouellet LJ. Needle exchange and sexual risk behaviors among a cohort of injection drug users in Chicago, Illinois. Sex Transm Dis. 2009;36(1):35–40.PubMedCentralPubMedCrossRef
83.
Huo D, Ouellet LJ. Needle exchange and injection-related risk behaviors in Chicago: a longitudinal study. J Acquir Immune Defic Syndr. 2007;45(1):108–14.PubMedCrossRef
84.
Donoghoe MC, Verster A, Pervilhac C, Williams P. Setting targets for universal access to HIV prevention, treatment and care for injecting drug users (IDUs): towards consensus and improved guidance. Int J Drug Policy. 2008;19(Suppl 1):S5–14.PubMedCrossRef
85.
Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285–301.PubMedCrossRef
86.
CDC. Public health and injection drug use. MMWR. 2001;50(19):377–99.
87.
Thorpe LE, Bailey SL, Huo D, Monterroso ER, Ouellet LJ. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997–1999). J Acquir Immune Defic Syndr. 2001;27(1):71–8.PubMedCrossRef
88.
89.
Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR. 2006;55(RR-14):1–17.PubMed
90.
Dowling-Guyer S, Johnson ME, Fisher DG, et al. Reliability of drug users’ self-reported HIV risk behaviors and validity of self-reported recent drug use. Assessment. 1994;1(4):383–92.
91.
Rhodes T, Stimson GV, Crofts N, Ball A, Dehne K, Khodakevich L. Drug injecting, rapid HIV spread, and the ‘risk environment’: implications for assessment and response. AIDS. 1999;13(Suppl A):S259–69.PubMed
92.
Crawford ND, Vlahov D. Progress in HIV reduction and prevention among injection and noninjection drug users. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S84–7.PubMedCentralPubMedCrossRef
93.
94.
CDC. Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary of guidance from CDC and the U.S. department of health and human services. MMWR. 2012;61(5):1–43.
95.
Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review. Int J Drug Policy. 2012;23(3):176–84.PubMedCrossRef
96.
Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol. 2003;22(4):332–9.PubMedCrossRef
97.
Latka MH, Hagan H, Kapadia F, et al. A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C. Am J Public Health. 2008;98(5):853–61.PubMedCentralPubMedCrossRef
98.
Mackesy-Amiti ME, Finnegan L, Ouellet LJ, et al. Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: a latent transition analysis of the CIDUS 3/DUIT Study. AIDS Beh. 2012;17(6):2075–83.CrossRef
99.
Vlahov D, Fuller CM, Ompad DC, Galea S, Des Jarlais DC. Updating the infection risk reduction hierarchy: preventing transition into injection. J Urban Health. 2004;81(1):14–9.PubMedCentralPubMedCrossRef
100.
Chatterjee S, Tempalski B, Pouget ER, Cooper HL, Cleland CM, Friedman SR. Changes in the prevalence of injection drug use among adolescents and young adults in large U.S. metropolitan areas. AIDS Beh. 2011;15(7):1570–8.CrossRef
101.
Young AM, Havens JR. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. Addiction. 2012;107(3):587–96.PubMedCentralPubMedCrossRef
102.
Grau LE, Dasgupta N, Harvey AP, et al. Illicit use of opioids: is OxyContin a “gateway drug”? The American journal on addictions/American Academy of Psychiatrists in Alcoholism and Addictions. 2007;16(3):166–73.PubMedCrossRef
Metadaten
Titel
Prevalence of HIV Infection and Risk Behaviors Among Younger and Older Injecting Drug Users in the United States, 2009
verfasst von
Dita Broz
Huong Pham
Michael Spiller
Cyprian Wejnert
Binh Le
Alan Neaigus
Gabriela Paz-Bailey
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe Sonderheft 3/2014
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-013-0660-4

Weitere Artikel der Sonderheft 3/2014

AIDS and Behavior 3/2014 Zur Ausgabe

Original Paper

Smoking and Experiences with Tobacco Cessation Among Men Who Have Sex with Men: New Orleans, 2011

Original Paper

Hepatitis B Virus (HBV) Infection, Immunity and Susceptibility Among Men Who Have Sex with Men (MSM), Los Angeles County, USA

Original Paper

Comparison of Surveillance Sample Demographics Over Two Cycles of the National HIV Behavioral Surveillance Project, Houston, Texas

Original Paper

Correlates of HIV Infection Among African American Women from 20 Cities in the United States

Original Paper

Factors Associated with Recent HIV Testing Among Men Who Have Sex with Men in New York City

Original Paper

Utilization of HIV Prevention Services Across Racial/Ethnic Groups Among Men Who Have Sex with Men in San Francisco, California, 2008

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise